Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Pulmonary And Respiratory Medicine

Anaplastic Lymphoma Kinase

Show all topics

DOI

10.1016/s1470-2045(18)30144-x

Other Formats

PDF